Cole D E, Gallinger S, McCready D R, Rosen B, Engel J, Malkin D
Department of Clinical Biochemistry, University of Toronto, Ont.
CMAJ. 1996 Jan 15;154(2):149-55.
Recent advances in our understanding of the genetic characteristics of cancer will change approaches to genetic screening and counselling. Cancer results from multiple, cumulative mutations in genes that regulate cell replication and differentiation. In familial cancer a germ-line mutation is passed on in an autosomal dominant pattern, but cancer will develop in people who inherit the defect only if other mutations also occur in susceptible somatic cells. The tumour-suppressor gene known as BRCA1 is thought to affect half of those families who have an inherited breast cancer syndrome and most families with a breast and ovarian cancer syndrome. Another gene, BRCA2, is thought to affect most of the remaining families with a breast-cancer-only syndrome. Hereditary nonpolyposis colon cancer (HNPCC) is caused by mutations in surveillance genes that protect DNA from the spontaneous errors that occur during cell division. Because there are no outcome data on which to base practice guidelines for genetic screening or management of asymptomatic carriers in families at risk, testing should be restricted to research settings.
我们对癌症遗传特征认识的最新进展将改变基因筛查和咨询的方法。癌症是由调节细胞复制和分化的基因发生多个累积突变所致。在家族性癌症中,种系突变以常染色体显性模式遗传,但只有当其他突变也发生在易感体细胞中时,继承了该缺陷的人才会患癌症。被称为BRCA1的肿瘤抑制基因被认为影响了一半患有遗传性乳腺癌综合征的家族以及大多数患有乳腺癌和卵巢癌综合征的家族。另一个基因BRCA2被认为影响了其余大多数仅患有乳腺癌综合征的家族。遗传性非息肉病性结直肠癌(HNPCC)是由监测基因的突变引起的,这些基因可保护DNA免受细胞分裂过程中发生的自发错误的影响。由于没有可用于制定针对有风险家族中无症状携带者进行基因筛查或管理的实践指南的结果数据,因此检测应仅限于研究环境。